Abstract Multispecific antibodies represent one of the most advanced and promising therapeutic modalities in contemporary biopharmaceutical development. Among the various design strategies for multispecific antibody assembly, common light-chain(CLC) antibodies and nanobodies offer substantial advantages. They inherently avoid light-chain mispairing, thereby markedly reducing the complexity of subsequent process development. Kyinno’s CLC mouse system is protected by global patent rights. Distinct from conventional approaches that introduce only partial heavy-chain germline elements into mice, Kyinno preserves the entire heavy-chain germline repertoire and pairs it with a fixed light-chain germline, which exhibits the highest compatibility with diverse heavy chains. This design minimizes the impact of genetic engineering on sequence diversity within the CLC system. For nanobody discovery, Kyinno operates a parallel system consisting of non-immunized alpaca and a heavy-chain-only mouse, ensuring both low off-target reactivity and high molecular diversity. In addition, Kyinno provides proprietary antigen optimization and immunization strategies that are particularly effective for challenging targets and the development of bispecific monoclonal antibodies. Thus, Kyinno’s antibody library and antibody development services offer innovative solutions that overcome the limitations of traditional technologies, thereby accelerating the development of next-generation antibody therapeutics. Citation Format: Yi Gu, Xinde Liu, Peng Li, Feng He, Feng Hao, JInying Ning, . (Common-light-chain-antibody+nano-body) × multi-matrix-immunization platform facilitates the development of antitumor multispecific antibody drugs abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 5851.
Gu et al. (Fri,) studied this question.